van Ommen C Heleen, Sol Jeanine J
Department of Pediatric Hematology, Erasmus MC Sophia Children's Hospital, Rotterdam, The Netherlands.
Department of Pediatrics, Groene Hart Hospital, Gouda, The Netherlands.
Semin Thromb Hemost. 2016 Oct;42(7):752-759. doi: 10.1055/s-0036-1592299. Epub 2016 Sep 16.
Neonatal hemostasis differs qualitatively, but in particular quantitatively, from hemostasis in older children and adults. Nevertheless, hemostasis in healthy neonates is functionally stable with no tendency to bleeding or thrombotic complications. In sick neonates, however, risk factors may disrupt this equilibrium and lead to thrombosis. The most important risk factor is the central venous catheter. Management of neonatal central venous catheter thrombosis is challenging, as no controlled trials have been performed. Therapeutic options include (1) observation and supportive treatment; (2) anticoagulant agents, including low-molecular-weight heparin and unfractionated heparin; (3) thrombolytic agents; and (4) thrombectomy. Prevention of thrombosis with anticoagulation is not advised yet. Careful consideration of the necessity of the catheter and optimal hygienic care are important preventative measures.
新生儿止血在性质上有所不同,尤其是在数量上,与大龄儿童和成人的止血情况不同。然而,健康新生儿的止血功能稳定,没有出血或血栓形成并发症的倾向。然而,在患病新生儿中,危险因素可能会破坏这种平衡并导致血栓形成。最重要的危险因素是中心静脉导管。新生儿中心静脉导管血栓形成的管理具有挑战性,因为尚未进行对照试验。治疗选择包括:(1)观察和支持治疗;(2)抗凝剂,包括低分子量肝素和普通肝素;(3)溶栓剂;(4)血栓切除术。目前不建议用抗凝剂预防血栓形成。仔细考虑导管的必要性和最佳卫生护理是重要的预防措施。